Introduction: Liver cancer is cancer that occurs in the liver. The liver is the largest internal organ of the body which performs several critical functions to help the body eliminate waste, absorb nutrients, and heal wounds. Liver cancer is generally classified as primary or secondary. Primary liver cancer begins in the cells of the liver. Secondary liver cancer develops when cancer cells from another organs spread to the liver, or metastasize. Liver cancer is the fourth most common cause of cancer-related deaths worldwide, with obesity, exacerbating the risk especially two times higher in Body Mass Index (BMI) above 30 and four times higher in BMI above 35. Also, The gene that has been the most strongly and frequently associated with susceptibility to obesity is the fat mass and obesity-associated (FTO) gene, which has most influence on body mass index (BMI) of all known genes.
Methods: Human saliva samples, DNA electrophoresis, NCBI and MagaGene Pharmacogenetic software
Results: According to this study, RS9939609, RS17782313 and RS1799883 polymorphisms are the most common obesity polymorphisms in Iran which can case obesity and increase the risk of liver cancer. About 12 drugs are used to control obesity. among these drugs, TSH causes headache in people with BRCA2 gene, VEGF increases blood glucose in people with FTO gene, Lira causes nausea in people Having MLH1 gene and Phent leads to hair loss and high blood pressure in people with FTO gene.
Conclusion: In order to use drugs to treat liver cancer, it is necessary to carry out genetic tests to check the presence of polymorphisms in common genes on patients such as FTO, MC4R and FABP2 before prescribing any drugs, therefore drugs with less side effects can be prescribed for these patients.